YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer.

Acta Pharm Sin B · 2022 · PMC9214057 · PMID 35755282

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

Meanwhile, the spleen index and the thymus index of mice showed an increasing trend after administration of YPD-30 ( Fig.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.